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Abstract 
Social deficits are key hallmarks of the Clinical High Risk for Psychosis (CHR-P) state and of 
established psychotic disorders, and contribute to impaired social functioning, indicating a potential 
target for interventions. However, current treatments do not significantly ameliorate social 
impairments in CHR-P individuals. Given its critical role in social behaviour and cognition, the 
oxytocinergic (OT) system is a promising target for novel interventions in CHR-P subjects. In a double-
blind, placebo-controlled, crossover design, 30 CHR-P males were studied using functional magnetic 
resonance imaging (fMRI) on two occasions, once after 40IU self-administered intranasal OT and 
once after placebo. A modified version of the Sally-Anne task was used to assess brain activation 
during inferring others’ beliefs and social emotions. The Reading the Mind in the Eyes Test was 
acquired prior to the first scan to test whether OT effects were moderated by baseline social-
emotional abilities. OT did not modulate behavioural performances but reduced activation in the 
bilateral inferior frontal gyrus compared with placebo while inferring others’ social emotions. 
Furthermore, the relationship between brain activation and task performance after OT 
administration was moderated by baseline social-emotional abilities. While task accuracy during 
inferring others’ social emotion increased with decreasing activation in the left inferior frontal gyrus 
in CHR-P individuals with low social-emotional abilities, there was no such relationship in CHR-P 
individuals with high social-emotional abilities. Our findings may suggest that acute OT 
administration enhances neural efficiency in the inferior frontal gyrus during inferring others’ social 
emotions in those CHR-P subjects with low baseline social-emotional abilities.   
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Introduction 
Deficits in social functioning are core features of psychosis and predictive for the onset, 
development, course and outcome of this illness.1 Social functioning impairments are a distinctive 
characteristic of individuals at Clinical High Risk for Psychosis (CHR-P) to the point that they represent 
the most impaired neurocognitive domain (Hedge’s g=0.55) in this patient population.2-4 However, 
currently available approaches for CHR-P individuals fail to ameliorate their social impairments, 
indicating the need for novel and more effective interventions that map onto core pathological 
processes underlying the CHR-P features.5, 6 Mind-reading, i.e., the ability to infer others’ mental 
states, is integral for social interactions7 and impaired in early psychosis patients8 and CHR-P 
subjects.9, 10 Mental state attribution or perspective taking is a complex multidimensional construct 
and involves the ability to infer the thoughts or beliefs of others (i.e. cognitive empathy), but also the 
ability to infer the emotions or feelings of others (i.e. emotional empathy).11 Past evidence showed 
that cognitive and emotional aspects of empathy are partly dissociable systems.12 While 
neurocognitive dysfunction significantly accounts for impairments during theory of mind (ToM) tasks 
in CHR-P individuals,10 they still remain evident after adjusting for deficits in neurocognition,8 
indicating the crucial contribution of impaired emotional empathy to ToM deficits in CHR-P. Meta-
analytical evidence identified the left anterior midcingulate cortex / dorsal anterior cingulate cortex, 
bilateral insula / inferior frontal gyrus and bilateral supplementary motor area as being consistently 
activated in empathy.13 While the bilateral anterior insula / inferior frontal gyrus is specifically 
activated during emotional empathy, activation in the left midcingulate cortex and left anterior insula 
is more related to the cognitive aspect of empathy.13 Previous functional magnetic resonance 
imaging (fMRI) studies in CHR-P individuals reported increased activation in the prefrontal cortex 
including the inferior frontal gyrus, posterior cingulate cortex and the temporoparietal cortex during 
inferring others’ mental status relative to healthy controls, suggesting a compensatory overactivation 
of brain regions critical for empathic responses during mental state attribution.14, 15 Another study 
observed reduced bilateral inferior frontal gyrus activation during inferring others’ emotions but not 
beliefs in CHR-P subjects relative to healthy subjects.16   
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Given its critical role in human social behaviour and cognition,17 the oxytocinergic (OT) system is a 
promising target for the treatment of social impairments in CHR-P subjects. OT has been proposed to 
be a key neural substrate that interacts with central dopamine systems18 and may counteract 
hyperdopaminergia seen in psychosis.19 Previous studies have reported altered blood OT levels in 
schizophrenia patients,20, 21 which predicted social cue recognition.21 CHR-P individuals show 
significantly decreased OT receptor gene methylation, which was related to increased anhedonia-
asociality.22 OT administration improves mind-reading23 and trust24 in healthy volunteers. Notably, OT 
affects emotional rather than cognitive empathy in healthy people25 and its effect on mind-reading 
depends on baseline social-emotional abilities.26 A single dose of OT also improves emotion 
recognition,27-29 higher-order social cognition (such as appreciation of indirect hints and recognition 
of social faux pas30), as well as working memory31 in schizophrenia patients. However, evidence for 
OT effects on cognitive and emotional empathy in early psychosis is sparse. A first study showed that 
24 IU for 6 weeks did not improve cognitive empathy in individuals with early schizophrenia-
spectrum psychotic illness.32   
 
This study investigated, for the first time, whether acute OT administration changed the ability to 
successfully infer on others people’s beliefs (cognitive empathy) and social emotions (emotional 
empathy) in CHR-P males, and whether this change goes along with altered neural activation. Based 
on previous evidence in healthy people25, 33 and CHR-P individuals,16 we expected that OT would 
enhance successful recognition of others’ facial emotions but not beliefs and that this improvement 
in successful social emotion inferences would be accompanied by increased neural activation in the 
emotional empathy network, in particular in the inferior frontal gyrus. As previously shown,26, 34 we 
further predicted that OT effects would be moderated by baseline social-emotional abilities, with 
CHR-P individuals low in social-emotional abilities showing greater improvements after OT 
administration.   
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Materials and Methods 
Participants 
The study received National Research Ethics Service approval (14/LO/1692) and all subjects gave 
written informed consent. The participants and OT administration have previously been described in 
our Arterial Spin Labelling (ASL)35 and magnetic resonance spectroscopy (1H-MRS)36 studies. Sample 
size was estimated using G*Power 3 to detect neurochemical effects based on a previous 1H-MRS 
study,37 which indicated that a sample size of 30 was sufficient to detect a medium within-subject 
effect size (dz=0.53), when alpha = 0.05 and power = 80%. Thirty male, help-seeking CHR-P individuals 
aged 18–35 were recruited from two specialist early detection services—the OASIS 38 and Tower 
Hamlets Early Detection Service (THEDS), which belongs to the Pan-London Network for Psychosis-
prevention (PNP).39 CHR-P status was assessed using the Comprehensive Assessment of At-Risk 
Mental States (CAARMS) 12/2006 criteria.40 In brief, subjects met one or more of the following 
subgroup criteria: (a) attenuated psychotic symptoms, (b) brief limited intermittent psychotic 
symptoms (BLIPS, psychotic episode lasting < 1 week, remitting without treatment41-43), or (c) either 
schizotypal personality disorder or first-degree relative with psychosis,40 all coupled with functional 
decline. Individuals were excluded if there was a history of previous psychotic disorder (with the 
exception of BLIPS, some of whom may meet Acute and Transient Psychotic Disorder criteria42) or 
manic episode, exposure to antipsychotics, neurological disorder or current substance-use disorder, 
estimated IQ < 70, acute intoxication on the day of scanning, and any contraindications to MRI or 
intranasal OT or placebo. History of Axis I disorder(s) was not an exclusion criterion due to the 
transdiagnostic nature of the CAARMS-based definition of the CHR-P state44 and the high prevalence 
of such diagnoses within these populations.45 We also collected information on medication history, 
alcohol (Alcohol Use Disorders Identification Test), tobacco and cannabis use, functioning (Global 
Functioning Role and Social scales46) and transition status. One subject reported cannabis use prior to 
one scan and was therefore excluded from analysis. Furthermore, to test for potential moderation 
effects of baseline social-emotional abilities on OT effects,26, 47 the Reading the Mind in the Eyes Test 
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(RMET48) was acquired prior to the first scan. RMET measures the ability to interpret subtle social-
emotional cues from the eye region.48 It compromised 36 photographs depicting the eye region of 
Caucasian posers. Stimuli were presented on a black background in the center of a computer screen. 
In the four corners around the picture, one target label and three distractors were simultaneously 
shown. Participants were asked to select the correct mental state as fast as possible. The picture 
remained on the screen until participants clicked on a label with the mouse. A practice trial was 
conducted, and a glossary was provided in paper form. Performance was determined by calculating 
the percentage of correct answers. Demographic and clinical characteristics of the sample are 
presented in Table 1.   
 
Study design  
Using a randomised, double-blind, crossover design, 40 IU intranasal OT and placebo were 
administered in a counterbalanced fashion with a 1-week wash out period. During each challenge, 
subjects underwent an MRI scan which started at 11:30 h to minimise potential effects of diurnal 
variation in OT or vasopressin.49 Intranasal OT administration followed recommended guidelines and 
a protocol adopted by a previous study conducted at our institute.49 As done in our previous 
studies,35, 36 participants self-administered one puff (4 IU) of intranasal OT or matched placebo every 
30s, alternating between nostrils, until 40 IU had been administered. See35, 36 for more details.   
 
Functional MRI paradigm 
A modified version of the Sally-Anne task was used as previously applied in individuals with autism 
spectrum disorder after OT administration.50 Participants underwent two runs consecutively, each of 
which lasted approximately 7.5 minutes. Each run consisted of 10 different stories (Supplementary 
Figure 1), while every story was presented three times in a row, one for each of the three conditions: 
‘control’, ‘belief inference (cognitive empathy)’ and ‘social emotion inference (emotional empathy)’. 
The identical set of 10 stories was presented during the first and second run. At the end of each story 
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participants were required to answer ‘yes–no’. Questions were presented in a pseudorandom 
fashion, so that ‘yes’ questions in the first run were modified to be ‘no’ questions in the second run, 
and vice versa. Before scanning, all participants were shown the cartoon stories in a mock scanner 
and required to answer questions as in the ‘control’ condition. In this manner, participants were 
trained to grasp the stories without experiencing the questions of the ‘Belief’ and ‘Social emotion’ 
conditions.   
Let’s take one story as an example. As summarized in Figure 1A, four frames show a story with two 
persons with neutral faces. During the story, one person (Sally) places a ball in a left box (Frame 1) 
and leaves the room (Frame 2). Meanwhile, another person (Anne) moves the ball to a right box 
(Frame 3) and then Sally returns (Frame 4). At the end of the story, participants are asked the 
following three types of questions in a pseudorandom order (Figure 1B): ‘Is the ball actually in this 
box? (indicating a left box with a star)’ for the control condition, ‘Does she look for her ball in this 
box? (indicating Sally with an arrow and a left box by a star)’ for the belief inference condition, and 
‘Does she feel playful, seeing the box opened?’ for the social emotion inference condition. To answer 
the first question (control condition), participants are required to understand the actual location of 
the ball. For the second question (belief inference), they are required to understand that Sally’s 
actions will be based on what she believes to be true, rather than the actual location. In the third 
question (social emotion inference), participants were required to answer the question about Anne’s 
emotional status after she completed the practical joke. To successfully infer on Anne’s emotional 
status, it is required not only to understand the story (control condition) but also that Anne believes 
that Sally falsely believes the ball is in the left box. In other words, successful social emotion 
inference (emotional empathy) depended on successful belief inference (cognitive empathy) but not 
vice versa. Task conditions and trial timing are summarized in Figure 1C. Each trial consisted of 3.5 s 
story presentation with four frames (cf. Figure 1A); 2 s question; 2.5–3.5 s fixation cross; 3 s of a 
frame with comic vignette that illustrates an arrow and a star to help to answer the question; and 3 s 
fixation cross. Participants were required to answer this question during the last frame with comic 
and fixation cross by pressing a button to answer yes or no.   
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Insert Figure 1 about here 
 
Behavioural analysis 
We measured accuracy and reaction time to correct responses during the task. Paired t-test was used 
to test OT effects for each task condition.   
 
Image acquisition and processing 
All scans were conducted on a General Electric Discovery MR750 3 Tesla system (General Electric, 
Chicago, USA) using a 32-channel head coil. During the task, we acquired T2*-weighted echo-planar 
images with the following parameters: 41 axial slices of 3 mm thickness, 0.3 mm interslice gap, field 
of view 24 x 24 cm2 and flip angle 75°. The repetition time was 2 s and the echo time 30 ms. EPIs 
were analysed using an event-related design with SPM12 (www.fil.ion.ucl.ac.uk/spm). Pre-processing 
was performed for each subject and time point separately. In brief, slice-timing correction was first 
performed on each volume using the middle slice as the reference to adjust for time differences due 
to multislice image acquisition. The images were then realigned to the first image in the series. The 
anatomical T1 image was co-registered with the first functional image and then spatially normalized 
into the MNI space, generating normalization parameters, which were applied to all functional 
images. Functional images were smoothed with a Gaussian kernel of 8 mm full half-width maximum 
(FWHM). All images were checked for movement artefacts and subjects with more than 10% 
corrupted volumes (all scans with more than 3 mm deviation from the previous scan in any 
dimension) were excluded (one subject). Voxel-wise maximum likelihood parameter estimates were 
calculated during the first-level analysis using the general linear model. Our design matrix included 
an autoregressive AR(1) model of serial correlations and a high-pass filter with a cut-off of 128 s. The 
onsets of each event were convolved with the SPM synthetic haemodynamic response function. Each 
event-related regressor had an onset at the time of the answer frame and a duration that correspond 
 10 
to each response time (cf. Figure 1C). First-level models were constructed for both treatments 
separately, including only the onset times for correct responses in the control, belief and social 
emotion condition during both runs. In line with previous studies using the same task,16, 50 this 
approach allowed us to study whether OT administration changed neural activation while 
successfully inferring others’ belief and social emotion relative to placebo. One subject had no 
correct responses during one of the four runs and was therefore excluded. The final sample thus 
consisted of 27 subjects. Two contrast images were generated per participant: ‘belief > control’ 
(cognitive empathy) and ‘social emotion > control’ (emotional empathy). One-sample t tests were 
conducted to test for effects of condition (cognitive and emotional empathy) after placebo 
administration and paired t-tests were conducted to test for treatment effects in the two 
interrelated contrasts of interest separately as previously done.50 Significance was assessed at a 
cluster-level threshold of p < 0.05 family-wise error (FWE) corrected across the whole brain with an 
uncorrected cluster-forming threshold of p < 0.001 51, 52 with an extent threshold of 20 voxels.   
 
Impact of baseline social-emotional abilities 
The relationship between baseline social-emotional ability (RMET performance) and significant brain 
effect (left inferior frontal gyrus) after OT administration was tested using Spearman correlation at a 
significance level of p < 0.05. Parameter estimates were extracted from the whole left inferior frontal 
gyrus cluster (300 voxels) showing a significant effect between OT and placebo during inferring 
others’ social emotions (‘social emotion > control’ contrast). Nonparameteric correlation was 
performed due to the fact that parameter estimates of left inferior frontal gyrus activation were not 
normally distributed as indicated by a significant Kolmogorov-Smirnov test (p = 0.033). We further 
used a linear regression to test whether the relationship between brain activation in left inferior 
frontal gyrus and task accuracy after OT administration was moderated by RMET performance. Task 
accuracy was entered as dependent variable and the interaction RMET x left inferior frontal gyrus 
activation as independent variable. To perform a parametric moderator analysis, parameter 
estimates in the left inferior frontal gyrus after OT administration were first log transformed.    
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Results 
Behavioural task performance 
OT did not modulate accuracy for the control (T=0.332, p=0.743), belief (T=0.618, p=0.542) or social 
(T=0.775, p=0.445) condition (Figure 2A). OT also did not influence reaction times for correct 
responses during the control (T=0.024, p=0.981), belief (T=0.801, p=0.430) or social (T=1.11, p=0.277) 
condition (Figure 2B). Correlations between reaction time and accuracy within and between the 
different task conditions are presented in Supplementary Table 1.   
Insert Figure 2 about here 
 
Brain activation 
Effect of conditions 
Inferring others’ beliefs (belief > control) evoked significant activation in left precuneus, angular 
gyrus, inferior frontal and parietal gyrus and bilateral middle frontal gyrus (Supplementary Table 2, 
Supplementary Figure 2A). Inferring others’ social emotions (social emotion > control) evoked 
significant activation in left supplementary motor area, superior frontal gyrus, inferior temporal 
gyrus, angular gyrus, precuneus, right cerebellum, and bilateral inferior and middle frontal gyrus, 
middle temporal gyrus and caudate (Supplementary Table 3, Supplementary Figure 2B).   
 
Effect of OT  
OT did not modulate brain activation during inferring others’ beliefs relative to placebo 
(Supplementary Table 4). However, during inferring others’ social emotions, OT significantly reduced 
activation in the left and right inferior frontal gyrus (Table 2, Figure 3A). No significantly increased 
activation was found after OT relative to the placebo adiminstration during inferring others’ social 
emotions (Supplementary Table 5). Notably, the differences in left (T=0.156, p=0.879) and right 
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(T=0.873, p=0.419) inferior frontal gyrus activation after OT relative to placebo did not differ 
between those individuals who received antidepressants (n=8) or not.   
 
Moderater effect of baseline social-emotional abilities on OT effects 
We further tested whether left inferior frontal gyrus activation after OT administration during 
inferring others’ social emotions (social emotion > control) was related to baseline RMET scores. 
There was a significant positive correlation between baseline RMET scores and left inferior frontal 
gyrus activation after OT administration  (r=0.388, p=0.046) (Figure 3B). We further found that RMET 
score also moderated the relationship between left frontal gyrus activation during inferring others’ 
social emotion and task accuracy after OT administration, as indicatined by a significant interaction 
RMET x left inferior frontal gyrus (=-3.53, p=0.020). The moderator effect was also evident after 
median (median = 26) splitting the sample into high (n=13) and low (n=14) RMET performance (=-
20.05, p=0.023). While task accuracy increased with decreasing activation in the left inferior frontal 
gyrus in CHR-P individual with low RMET scores (r=-0.578, p=0.030), there was no significant 
relationship between task accuracy and left inferior frontal gyrus activation in CHR-P individual with 
high RMET scores (r=0.088, p=0.775) (Figure 3C).   
Insert Figure 3 about here 
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Discussion 
To our knowledge, this is the first fMRI study to assess how acute OT administration modulated brain 
activation during inferring others’ beliefs and social emotions in CHR-P individuals. The first main 
finding is that OT did not affect brain responses during belief inference (cognitive empathy) but 
reduced activation in the bilateral inferior frontal gyrus during social emotion inference (emotional 
empathy). The second main finding is that neural activation in the left inferior frontal gyrus during 
social emotion inference after OT administration was modulated by baseline social-emotional 
abilities, which also moderated the relationship between brain activation and task performance. 
These findings can inform subsequent experimental therapeutics in this patient population.  
 
The first finding of this study is that while OT did not modulate neural responses during belief 
inference it did reduce neural activation in the bilateral inferior frontal gyrus during social emotion 
inference. OT has been shown to enhance emotional but not cognitive empathy in healthy 
participants,25, 33 an effect that could be replicated across culture and sex.53 In early psychosis 
patients, OT treatment did not enhance cognitive empathy but improved the ability to recognize 
emotions in schizophrenia patients.27 We add to this line of evidence by showing that OT significantly 
decreased activation in the bilateral inferior frontal gyrus during emotional but not cognitive 
empathy in CHR-P subjects. The inferior frontal gyrus has been increasingly implicated in emotion 
recognition tasks such as identification of emotional intonation,54 judgment of facial expressions55 
and is an essential part of the neural mirror system, which is involved in a variety of important social 
behaviours, from imitation to emotional empathy.56 Good imitation facilitates recognizing emotions 
in other people and thus emotional empathy.57 Previous seminal work demonstrated that patients 
with inferior frontal gyrus lesions displayed extremely impaired emotional but not cognitive 
empathy.12 More importantly, a previous study that used the same fMRI task in CHR-P found reduced 
activation in the bilateral inferior frontal gyrus when inferring others emotions but not beliefs 
relative to healthy controls.16 The inferior frontal gyrus is a core target of the neurofunctional effects 
of OT.58 OT may promote assimilation of novel emotional experiences into internal models,59 which is 
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supported by parts of the left inferior frontal gyrus.60 Emotion perception is impaired in patients with 
schizophrenia,1 CHR-P subjects,61 offspring of parents with schizophrenia62 and is related to poor 
functional outcomes.1, 61 As a potential compensatory mechanism for this deficit, stronger inferior 
frontal gyrus activation during emotional perspective-taking has been observed in CHR-P subjects 
compared with healthy controls.14, 15 Given that task performance during emotional empathy did not 
differ between OT and placebo in the current study, decreased inferior frontal gyrus activation after 
OT administration might indicate enhanced neural efficiency. Such an interpretation corresponds 
with a recent study showing that OT enhances neural efficiency of social perception as expressed by 
reduced event-related potential latencies.63 Taken together, we might speculate that after receiving 
placebo, CHR-P subjects compensated their deficits in emotional perspective-taking by increasing 
activation in the inferior frontal gyrus compared with healthy individuals, as previously shown,14, 15 
whereas OT may enhance neural efficiency in the inferior frontal gyrus by normalizing activation to 
the level of healthy persons.   
 
The second main finding was of a positive relationship between baseline social-emotional abilities 
and left inferior frontal gyrus activation during social emotion inference (emotional empathy) after 
OT administration. Moreover, baseline social-emotional abilities as expressed by RMET performance 
moderated the relationship between OT-induced task performance and inferior frontal gyrus 
activation during emotional empathy. In particular, whereas inferior frontal gyrus activation 
decreased with increasing task performance in CHR-P subjects with low baseline social-emotional 
abilities, no such relationship was found in CHR-P subjects with high baseline social-emotional 
abilities. These findings suggest that OT-induced improvement in neural efficiency as expressed by 
decreased activation in the inferior frontal gyrus only took place in those CHR-P subjects with low 
baseline social-emotional abilities. In other words, CHR-P subjects with low social-emotional abilities 
needed less activation in the inferior frontal gyrus to achieve comparable task performance as after 
placebo administration. This finding resonates with previous reports demonstrating that OT 
selectively improved mind-reading as assessed with the RMET in those individuals with low 
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emotional empathy,26 high in alexithymia or high in maternal love withdrawal.34, 64, 65 Although RMET 
performance has mostly been associated with cognitive empathy,26 a recent study demonstrated 
that the RMET measures emotion recognition rather than theory of mind (i.e. cognitive empathy) 
ability.66 Taken together, there is emerging evidence that OT influences emotional rather than 
cognitive processing and that its benefit depends on emotional empathy capacity.  
 
There are several possible clinical implications. The dearth of preventive treatments that can 
effectively impact clinical outcomes—in particular social functioning deficits— can be partially 
explained by lack of clear aetiopathological mechanisms underlying the therapeutic effects of 
preventive agents. This study advances knowledge in this area by providing the first disease target-
engagement evidence in CHR-P individuals. These neurophysiological results can inform the 
development of subsequent randomised controlled trials investigating OT’s effects on CHR-P 
symptoms and on clinical outcomes. Identifying novel therapeutic target for outcomes other than 
psychosis onset is a mainstream of future research in this area, considering that most CHR-P 
individuals who will not transition to psychosis will still display social functioning deficits at follow-up 
.67 
 
The present study has limitations. No healthy control group was included in the current study. 
However, we have used a fMRI task which was already tested in CHR-P vs. healthy controls,16 
demonstrating significant alterations in key brain areas that are also implicated in this study. Due to 
sex differences in brain responses to OT during social interaction,68 only male subjects were included. 
Another limitation is that this study did not collect extensive data on negative symptoms or 
neurocognition. Dose-response assessments are further required to test whether lower dosing might 
be sufficient for optimal target engagement, i.e. improving neural efficiency in the inferior frontal 
gyrus. While this study demonstrated that acute OT administration modulates key brain regions 
during inferring others’ social emotions, OT effects on functional outcomes in CHR-P subjects need to 
be tested in future longer-term clinical trials. Furthermore, in terms of the neurophysiological 
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mechanisms by which OT has its effects, we previously reported that OT modulates cerebral 
(hippocampal) perfusion in CHR-P patients,35 but did not appear to modulate regional concentrations 
of neurochemical metabolites.36 The mechanisms by which OT increases neural efficiency in CHR-P 
individuals therefore warrants further research. A final limitation is that because of the small sample 
size we have been unable to stratify the heterogeneous CHR-P group across its three main 
subgroups.69  
In conclusion, the present study provides the first evidence that acute OT administration modulates 
brain regions while inferring others’ social emotions in CHR-P subjects. Abnormal emotion perception 
persists over the course of the illness70 and is predictive for poor functional outcomes in CHR-P 
subjects.61 This study may thus provide neural targets to develop novel treatments for socio-
emotional deficits in CHR-P subjects with the aim to improve functional outcomes.   
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Figure legends 
Figure 1. Task design. A) Each story consisted of four frames with two people. There are 10 different 
types of stories (see supplementary Figure 1). B) Each story was presented three times consecutively 
per each run. At the end of each story presentation, participants were asked to answer the following 
three types of questions that asked emotion of the character, belief of the character, and fact 
(control condition). These three questions appeared in a pseudo-random order, followed by an 
answer frame. C) Trial timing. 3.5 s story presentation with four frames of a black and white comic. 
Then, a frame with a question written in white letters on the black screen was shown  for 2 s. After 
2.5–3.5 s white fixation cross on the black screen, another frame was presented to illustrate an arrow 
and a star to help to answer the question (3 s). At the end of one story, a 3-s fixation cross was 
shown. During the last frame and fixation cross, participants were instructed to answer the question 
with yes or no.  
 
Figure 2. Accuracies and reaction times in response to correct responses for both treatments during 
the task.   
 
Figure 3. A) Significant reduced activation in the left and right inferior frontal gyrus (IFG) during 
inferring others’ social emotion (social emotion > control) after OT compared with the placebo 
administration. Images are displayed at a cluster-forming threshold of p < 0.001 uncorrected, with an 
extent threshold of 20 voxels. Colour bars indicate t values. B) Significant correlation between left 
IFG activation after OT administration (i.e. parameter estimate, PE) during inferring others’ social 
emotion and baseline RMET performance (r=0.388, p=0.046). C) Moderator effect of baseline RMET 
performance on the relationship between left IFG activation after OT administration (i.e. parameter 
estimate, PE) and task accuracy during inferring others’ social emotions after OT administration.   
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Tables  
Table 1. Participant demographic and clinical characteristics 
Demographic Age years; mean (SD) 22.48 (4.68) 
Age range. years 18-34 
Sex; male/female 30/0 
Ethnicity 
(White/Black/Asian/Mixed) 15/5/3/4 
Handedness. right/left 23/4 
Education. years; mean (SD) 13.33 (1.9) 
Clinical CHR-P Subtypea (BLIPS/APS/GRD) 5/21/1 
CAARMS attenuated positive 
symptomsb; mean (SD) 11.85 (3.44) 
Baseline anxiety scorec; mean (SD) 35.07 (9.83) 
GF social score; mean (SD) 6.85 (1.46) 
GF role score; mean (SD) 7.04 (1.63) 
RMETd; mean (SD), median 25.38 (4.99), 26 
Substance Use 
 
Current antidepressant medication 
(yes/no)* 8/19 
 Current antipsychotic medication 
(yes/no) 0/27 
 Current benzodiazepine medication 
(yes/no) 0 / 27 
 Current smoker (yes/no) 15/12 
 Cigarettes/day; mean (SD) 9.33 (6.29) 
 Cannabis usee; median (range) 2 (0-4) 
 Alcohol. AUDIT total; mean (SD) 6.74 (7.22) 
 
a Comprehensive Assessment of At-Risk Mental States (CAARMS) subgroup; BLIPS brief limited 
intermittent psychotic symptoms, APS attenuated psychotic symptoms, GRD genetic risk and 
deterioration 
b Sum of the global (severity) ratings for positive subscale items (P1-P4) of the CAARMS  
c Mean of pre-scan anxiety scores across conditions as measured by the State Trait Anxiety Inventory 
(STAI) 
d Reading the Mind in the Eyes Test (RMET) score at the initial clinical assessment.  
e Cannabis use: 0 = never, 1 = experimental use (tried occasionally), 2 = occasional use (small 
quantities from time to time), 3 = moderate use (moderate quantities regularly / large amounts 
occasionally), 4 = severe use (frequently used large quantities, often to intoxication/debilitation).  
 26 
Abbreviations: AUDIT, alcohol use disorders identification test; CHR-P, clinical high risk for psychosis; 
GF, global functioning (role and social) scale;  
* three subjects received Sertraline (20mg, 25mg and 100mg), one Escitalopram (20mg), one 
Mirtazapine (30mg), one Amitriptyline (10mg), one Fluexetine (40mg) and one received 300mg of 
unknown type.  
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Table 2. Treatments effects (placebo > OT) during inferring others’ social emotion (‘social emotion > 
control’) 
Region, Hemisphere pFWE, 
Cluster-level 
Cluster size 
pFWE 
T 
value 
Z 
value 
MNI coordinates 
(x/y/z) 
Inferior Frontal Gyrus, L 0.039 300 6.05 4.63 -48 18 -4 
Inferior Frontal Gyrus, L   5.26 4.22 -30 36 -8 
Inferior Frontal Gyrus, L   4.69 3.89 -56 16 2 
Inferior Frontal Gyrus, R 0.042 294 5.52 4.36 48 26 -4 
Inferior Frontal Gyrus, R   4.99 4.07 32 34 -8 
Parahippocampus, R 0.563 71 4.68 3.88 30 -10 -28 
Hippocampus, R   4.00 3.45 20 -10 -16 
Middle temporal gyrus, R 0.099 216 4.65 3.87 58 -42 -4 
Middle temporal gyrus, R   4.30 3.65 66 -36 -2 
Inferior temporal gyrus, R   3.68 3.23 64 -44 -10 
Postcentral gyrus, R 0.200 157 4.16 3.56 42 -22 34 
Postcentral gyrus, R   3.93 3.40 36 -26 42 
Postcentral gyrus, R   3.75 3.28 42 -28 58 
Middle temporal gyrus, L 0.742 45 4.14 3.54 -60 -38 6 
Calcarine, L 0.778 40 4.09 3.51 -26 -70 8 
Calcarine, L   4.00 3.45 -24 -62 12 
Putamen, L 0.854 29 4.08 3.50 -34 -10 -4 
Parahippocampus, R 0.841 31 4.07 3.50 12 -22 -12 
Cerebellum, L 0.899 22 3.95 3.42 -8 -42 -22 
 
FWE, family-wise error 
 
